What are the latest advances in Hereditary multiple exostoses?

TL;DR: Research into hereditary multiple exostoses (HME) is shifting from purely surgical management toward understanding the underlying molecular pathways, specifically the roles of heparan sulfate and the EXT1/EXT2 genes. While no curative medication currently exists, recent breakthroughs in small-molecule therapies and natural history studies are paving the way for future precision medicine interventions.

What are the most promising research directions for hereditary multiple exostoses?

The current research landscape for hereditary multiple exostoses is increasingly focused on the Wnt/β-catenin and BMP signaling pathways. Because hereditary multiple exostoses is caused by mutations in the EXT1 or EXT2 genes—which encode enzymes responsible for heparan sulfate polymerization—scientists are investigating how the loss of these enzymes alters cellular communication during bone development. Researchers are exploring how normalizing these signaling pathways might prevent the formation or expansion of osteochondromas, the hallmark benign tumors seen in hereditary multiple exostoses.

What recent breakthroughs have been made in managing hereditary multiple exostoses?

While surgery remains the standard of care for symptomatic tumors, clinical research is evolving. Recent international studies, including those involving the 266 members of the hereditary multiple exostoses community on DiseaseMaps.org, have highlighted the importance of standardized quality-of-life assessments. A significant recent focus has been on "natural history studies," which are observational trials that track how hereditary multiple exostoses progresses over time. These studies are essential because they provide the baseline data required by regulatory agencies like the FDA to approve future pharmacological treatments. There is also emerging interest in using advanced 3D imaging to monitor tumor growth rates more precisely than traditional X-rays.

Are there new diagnostic tools or clinical trials for hereditary multiple exostoses?

Diagnostic tools are becoming more sophisticated, with genetic testing now readily identifying the causative EXT1 or EXT2 mutations in approximately 90% of individuals with a clinical diagnosis of hereditary multiple exostoses. Regarding clinical trials, the field is currently transitioning from basic science to translational research. While there are currently no FDA-approved medications specifically for this condition, the following avenues are being explored in research settings:

• Natural History Studies: Longitudinal data collection to define clinical endpoints for future drug trials.


• Signaling Inhibitors: Investigational studies exploring small-molecule inhibitors that target overactive bone growth pathways.


• Surgical Innovation: Research into minimally invasive techniques to reduce recovery time and recurrence rates after tumor resection.


• Biomarker Discovery: Identifying serum or urine markers that correlate with disease activity to monitor tumor growth without excessive radiation exposure.

How can patients participate in research?

Patient participation is the most critical driver of progress for rare conditions like hereditary multiple exostoses. Because the patient population is small, every contribution to a registry or trial is statistically significant. Patients can search for ongoing studies on ClinicalTrials.gov by entering the term "Hereditary Multiple Exostoses" or "Multiple Osteochondromas." It is highly recommended that patients coordinate with their orthopedic oncologist or medical geneticist before enrolling in any trial to ensure it aligns with their current health status and long-term care plan.

Next steps

• Consult with a medical geneticist to confirm your EXT1 or EXT2 mutation status.


• Register with the DiseaseMaps.org community to connect with other patients and share your experiences.


• Regularly check ClinicalTrials.gov for updates on new recruitment phases.


• Engage with the MHE Research Foundation to stay informed about patient-led research initiatives.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always consult with a qualified healthcare provider regarding any medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Hereditary multiple exostoses.


• Orphanet: Multiple osteochondromas (Hereditary multiple exostoses).


• OMIM (Online Mendelian Inheritance in Man): Entry #133700 (EXT1) and #133701 (EXT2).


• MHE Research Foundation: Clinical research and advocacy resources.